Brand Intelligence Graph
Company Overview
About Be Biopharma
Be Biopharma uses CRISPR to engineer a patient's own B cells into continuous protein-secreting factories — a one-time treatment designed to replace lifelong enzyme replacement therapy for rare metabolic diseases. The company has raised $274 million in total financing including a $92 million Series C co-led by Nextech Invest and Bristol Myers Squibb, with ARCH Venture Partners as a continuing investor, and has an active Phase 1/2 trial (BeCoMe-9) for BE-101 in Hemophilia B.
Business Model & Competitive Advantage
B cells are uniquely suited for this approach: they naturally produce antibodies in large quantities, are long-lived in vivo, and can be engineered ex vivo without the viral vector constraints of other gene therapy approaches. By replacing the B cell's antibody-producing program with a therapeutic protein payload via CRISPR, Be Bio creates a personalized, long-duration protein delivery system that the patient's own immune architecture sustains.
Competitive Landscape 2025–2026
Bristol Myers Squibb's co-investment is the most significant commercial signal: BMS has one of the world's largest rare disease and hematology portfolios, and its investment thesis is likely rooted in the platform's potential to replace BMS's existing enzyme replacement therapy products with a one-time cure approach. Hemophilia B data from the Phase 1/2 trial in 2026 will be the first human validation of engineered B cell protein secretion durability.
Key Differentiators
Emerging Innovator
Be Biopharma is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Be Biopharma with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Be Biopharma? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Be Biopharma Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Be Biopharma vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →